May 1, 2005Vascular Medicine
Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA
Key result
Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, is positively correlated with insulin resistance and may contribute to endothelial dysfunction.
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
No immediate clinical role for ADMA assessment; leaves open causal confirmation and targeted interventions in endothelial dysfunction.
PICO
P
Population
Insulin resistance syndrome
E
Exposure / Comparator
Asymmetric dimethylarginine (ADMA)
The endogenous nitric oxide synthase inhibitor ADMA may play a mechanistic role in the development of insulin resistance and associated endothelial dysfunction.
Cite This Study
Sydow et al. (2005) conducted a review in Insulin resistance syndrome. Asymmetric dimethylarginine (ADMA) was evaluated. Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, is positively correlated with insulin resistance and may contribute to endothelial dysfunction.